Lung cancer is the leading cause of cancer deaths worldwide, with approximately 1.8 million people dying from this disease each year. Most patients are diagnosed after symptoms have appeared and the disease has progressed to an advanced stage (Stage III or IV), which explains the current worldwide five-year survival rate of just 20 percent. In contrast, the survival rate for small lung tumors that are treated at Stage 1A is as high as 90 percent. This significant difference highlights a critical
Read More
Liver Cancer Awareness – Here’s What You Need to Know in 2023
By the end of 2022, nearly 42,00 new cases of primary liver cancer will be diagnosed in the United States. In fact, liver cancer incidence rates have more than tripled since 1980, marking an increased need for better detection and diagnosis. We might not talk about liver cancer as much as we do breast or lung cancer, but it’s a real threat to millions of Americans – and we need to continue spreading awareness. Early detection is especially critical in treating liver cancer.
Read More
Oatmeal Health Brings AI-Powered Lung Cancer Screening to The Clinic in Oklahoma
What You Should Know: - Central Oklahoma Family Medical Center FQHC (The Clinic) has selected Oatmeal Health, a veteran-owned Patient Success Service to bring tech-enabled lung cancer screenings to their patients. - As part of the partnership, Oatmeal Health will provide white-glove, concierge service, offering our support without FQHC’s shouldering the burden or cost. Tech-Enabled Lung Cancer Screening Currently, lung screening rates hover at around 4 percent
Read More
ChristianaCare Spins Out New Gene Editing Company, CorriXR Therapeutics
What You Should Know: - ChristianaCare recently announced it has spun out its first commercial biotechnology private startup company, named CorriXR Therapeutics. The company will use CRISPR gene editing technology to develop new, clinically relevant oncologic therapeutics in areas of unmet medical need, starting with squamous cell carcinoma of the lung. Its close relationship with ChristianaCare and the ChristianaCare Gene Editing Institute uniquely positions it to research and develop
Read More
Optellum Raises $14M for AI-Enabled Lung Cancer Diagnosis
What You Should Know: - Optellum, an Oxford-based digital health company that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer raises $14M in Series A funding led by Mercia, with additional investors Intuitive Ventures and Black Opal Ventures. Existing investors, including St John's College in the University of Oxford, IQ Capital, and the family office of Sir Martin & Lady Audrey Wood, also participated in this round. - The investment will enable
Read More
Freenome Launches Multi-Cancer Detection Study Pairing Multiomics with Real-World Data
What You Should Know: - Freenome, a privately held biotech company, today announced the launch of the Sanderson Study, the company’s latest study of its multiomics platform, in combination with real-world data to detect multiple cancers. - The study will encompass both traditional and real-world data to generate evidence of clinical validation for certain high- and elevated-risk populations while also refining the platform’s cancer classification and risk prediction models. In addition,
Read More
Intelerad Acquires PenRad Technologies
What You Should Know: - Today, Intelerad, a leading global provider of enterprise medical imaging solutions, announced its acquisition of PenRad, a software provider for enhancing productivity for breast imaging and lung screening. - The acquisition expands Intelerad’s product offerings for mammography and lung analytics, ensuring radiologists, technologists and other healthcare professionals can drive greater productivity and meet higher oncology screening demand, while improving patient
Read More
UCLA Research Uses Saliva to Detect Cancer Biomarkers
What You Should Know: - Spectrum Solutions, LLC announced the publishing of findings from their research collaboration with the University of California at Los Angeles (UCLA) and Dr. David Wong, UCLA School of Dentistry that successfully demonstrated a superior ability to detect circulating tumor DNA (ctDNA) from saliva. - Specifically, amplified EGFR mutations associated with non-small cell lung cancer (NSCLC) using Spectrum’s saliva collection and preservation system with the Electric
Read More
$3.7 Trillion Reasons to Centralize Chronic Disease Management
59% of all Americans (194 million) suffer from at least one chronic disease, and almost one in three adults has three or more chronic conditions. Unfortunately, the problem will only get worse with time. On the business front of chronic disease management, health care systems are already struggling with rising costs and uneven quality despite the hard work of well-intentioned, well-trained clinicians. Health care leaders and policymakers have tried countless
Read More
Potential of Implementing Polygenic Risk Scores in Healthcare Systems
The promise of personalized medicine is a world in which interventions, screening, and therapeutics are targeted to those most likely to get the disease. Polygenic risk scores will help society reach this ambition by accurately assessing the contribution that one’s DNA makes to disease risk. When Thomas Jefferson wrote in the Declaration of Independence that ‘all men are created equal,’ he captured the essential concept of equality on which the US Constitution is based. Although no one would
Read More
